JP2008505087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008505087A5 JP2008505087A5 JP2007519344A JP2007519344A JP2008505087A5 JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5 JP 2007519344 A JP2007519344 A JP 2007519344A JP 2007519344 A JP2007519344 A JP 2007519344A JP 2008505087 A5 JP2008505087 A5 JP 2008505087A5
- Authority
- JP
- Japan
- Prior art keywords
- glucagon
- insulin
- amount
- milliunits
- units
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 52
- 102000051325 Glucagon Human genes 0.000 claims 43
- 108060003199 Glucagon Proteins 0.000 claims 43
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 43
- 229960004666 glucagon Drugs 0.000 claims 43
- 102000004877 Insulin Human genes 0.000 claims 26
- 108090001061 Insulin Proteins 0.000 claims 26
- 229940125396 insulin Drugs 0.000 claims 26
- 230000002218 hypoglycaemic effect Effects 0.000 claims 9
- 208000013016 Hypoglycemia Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 239000012731 long-acting form Substances 0.000 claims 4
- 102000007327 Protamines Human genes 0.000 claims 3
- 108010007568 Protamines Proteins 0.000 claims 3
- 229940048914 protamine Drugs 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000003443 Unconsciousness Diseases 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58444904P | 2004-06-29 | 2004-06-29 | |
PCT/US2005/022812 WO2006004696A2 (en) | 2004-06-29 | 2005-06-27 | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008505087A JP2008505087A (ja) | 2008-02-21 |
JP2008505087A5 true JP2008505087A5 (enrdf_load_stackoverflow) | 2008-07-31 |
Family
ID=35783298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007519344A Pending JP2008505087A (ja) | 2004-06-29 | 2005-06-27 | インスリン誘発性低血糖の予防および制御のための組成物ならびに方法 |
Country Status (11)
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2816114C (en) | 2010-11-03 | 2019-02-12 | Jan Jezek | Novel composition comprising glucagon |
EP3344231B1 (en) * | 2015-09-04 | 2022-04-13 | Latitude Pharmaceuticals, Inc. | Stabilized glucagon solutions |
GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
EP3576748B1 (en) * | 2017-02-03 | 2023-04-05 | Vanderbilt University | Systems, compositions and methods for treating diabetes |
CN110913888A (zh) * | 2017-07-14 | 2020-03-24 | Xeris药物公司 | 治疗先天性高胰岛素血症的方法 |
WO2019108640A1 (en) * | 2017-11-28 | 2019-06-06 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods and kits for evaluating metabolism |
MX2022016265A (es) * | 2020-06-26 | 2023-02-09 | Xeris Pharmaceuticals Inc | Composiciones terapeuticas de liberacion sostenida estable en solventes polares aproticos y metodos de preparacion de los mismos. |
GB202109087D0 (en) * | 2021-06-24 | 2021-08-11 | Norwegian Univ Sci & Tech Ntnu | Therapeutic methods and devices |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3897551A (en) * | 1971-04-05 | 1975-07-29 | Lilly Co Eli | Iodoglucagons and process for prolonging the biological activity of glucagon |
US5321008A (en) * | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
WO2004046106A1 (en) * | 2002-11-18 | 2004-06-03 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
CA2509755A1 (en) * | 2002-12-27 | 2004-07-22 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
-
2005
- 2005-06-27 ZA ZA200700708A patent/ZA200700708B/xx unknown
- 2005-06-27 WO PCT/US2005/022812 patent/WO2006004696A2/en active Application Filing
- 2005-06-27 CN CNA2005800270476A patent/CN101001638A/zh active Pending
- 2005-06-27 KR KR1020077002164A patent/KR20070029276A/ko not_active Withdrawn
- 2005-06-27 EP EP05787795A patent/EP1778266A4/en not_active Withdrawn
- 2005-06-27 AU AU2005260025A patent/AU2005260025A1/en not_active Abandoned
- 2005-06-27 CA CA002571030A patent/CA2571030A1/en not_active Abandoned
- 2005-06-27 JP JP2007519344A patent/JP2008505087A/ja active Pending
- 2005-06-27 MX MXPA06014970A patent/MXPA06014970A/es not_active Application Discontinuation
-
2006
- 2006-12-26 IL IL180361A patent/IL180361A0/en unknown
-
2007
- 2007-01-10 NO NO20070174A patent/NO20070174L/no not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2023237119B2 (en) | Buffered formulations of exendin (9-39) | |
AU2015204491B2 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
Gough et al. | Insulin degludec: overview of a novel ultra long‐acting basal insulin | |
JP2020033360A5 (enrdf_load_stackoverflow) | ||
HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
JP2019517542A5 (enrdf_load_stackoverflow) | ||
JP2021503468A5 (enrdf_load_stackoverflow) | ||
JP2014524480A5 (enrdf_load_stackoverflow) | ||
JP2005501110A5 (enrdf_load_stackoverflow) | ||
JP2005520778A5 (enrdf_load_stackoverflow) | ||
HRP20150186T1 (hr) | Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine | |
JP2013522194A5 (enrdf_load_stackoverflow) | ||
AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
ES2922551T3 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
CA2971440C (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
RU2016101064A (ru) | Состав с постоянным соотношением инсулина гларгина/ликсизенатида | |
JP2020500864A5 (enrdf_load_stackoverflow) | ||
JP2008505087A5 (enrdf_load_stackoverflow) | ||
JP2010516671A (ja) | 糖尿病の治療のためのエクセナチド及びダラルギンに基づく医薬、その使用及び治療方法 | |
Becker et al. | Dose-response relationship of insulin glulisine in subjects with type 1 diabetes | |
JP2022540198A (ja) | 組合せ | |
CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
CA2492378A1 (en) | Modified amino acid for the inhibition of platelet aggregation | |
CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
Wu et al. | Dipeptidyl peptidase IV (DPP IV): a novel emerging target for the treatment of type 2 diabetes |